J&J Seeks Approval For Doxil Plus Velcade In Multiple Myeloma
This article was originally published in The Pink Sheet Daily
Executive Summary
Supplemental claim for liposomal doxorubicin has a May 21 priority review date, J&J’s Ortho Biotech unit tells “The Pink Sheet” DAILY.
You may also be interested in...
J&J’s Doxil Approved For Use With Velcade In Second-Line Multiple Myeloma
Combination will be detailed by J&J’s oncology sales force under copromotion agreement with Velcade maker Millennium.
J&J’s Doxil Approved For Use With Velcade In Second-Line Multiple Myeloma
Combination will be detailed by J&J’s oncology sales force under copromotion agreement with Velcade maker Millennium.
Millennium Chief Medical Officer Nancy Simonian: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Exec discusses the firm's first year of profitability, the multiple myeloma market and current Velcade strategy following its copromotion deal with J&J.